首页|中药创新药知识产权综合性保护体系的初探——基于以岭药业连花清瘟方的实证分析

中药创新药知识产权综合性保护体系的初探——基于以岭药业连花清瘟方的实证分析

Preliminary study on the comprehensive protection system of intellectual property of innovative Chinese medicine:based on the empirical analysis of Lianhua Qingwen products manufactured by Yiling Pharmaceutical

扫码查看
中药复方的创新是中医药的研究热点,目前创新主体缺乏系统性策略来灵活运用各种形式的保护制度,在现行法律及规范下,研究中药创新药的知识产权综合性保护体系是有必要的.本文运用了实证分析的方法,通过深度挖掘以岭药业涉及连花清瘟方的专利、行政保护、商标、外观设计等情报信息,对于完善中药创新药知识产权综合性保护体系进行了初探.创新主体应当灵活运用行政保护、专利、商业秘密制度,将各种保护制度有机衔接,从而进行更为全面、系统综合保护.
The innovation of Chinese herbal formula is the research hotspot of traditional Chinese medicine.At present,innovation subjects lack systematic strategies to flexibly apply various forms of protection systems.In terms of current laws and regulations,it is necessary to study the comprehensive protection system of intellectual property of innovative Chinese medicine.This article used empirical analysis methods to deeply explore the patent,administrative protection,trademark,appearance design and other intelligence information related to Lianhua Qingwen products manufactured by Yiling Pharmaceutical and conducted a preliminary exploration on improving the comprehensive protection system of intellectual property of innovative Chinese medicine.Innovation subjects should flexibly apply administrative protection,patent,and business secret protection system and organically link various forms of protection system to achieve more comprehensive and systematic comprehensive protection.

innovative Chinese medicineintellectual propertycomprehensive protectionLianhua Qingwenempirical analysis

周佳、毛骥、薛姣、何华山

展开 >

国家知识产权局专利局专利审查协作江苏中心,苏州 215000

中药创新药 知识产权 综合性保护 连花清瘟方 实证分析

国家知识产权局专利局专利审查协作江苏中心自主课题研究项目(2022)

jszx202206

2024

中国新药杂志
中国医药科技出版社 中国医药集团总公司 中国药学会

中国新药杂志

CSTPCD北大核心
影响因子:1.039
ISSN:1003-3734
年,卷(期):2024.33(8)
  • 17